Beijing, China – August 2026 – Daxiang Biotech has been awarded Second Prize in the Finals of the HICOOL 2026 Global Entrepreneurship Competition, recognizing the company's innovation and commercialization efforts in organoid-on-chip technology.

Daxiang participated in the Growth-Stage category, presenting its work in the development and application of organoid-on-chip technologies for biomedical research and drug development.

HICOOL brings together entrepreneurs and technology ventures from around the world across emerging fields including biomedicine, artificial intelligence, advanced materials, and other frontier technologies. The 2026 competition attracted more than 10,000 projects from 141 countries and regions, with 48 projects advancing to the final round.

Advancing Organoid-on-Chip Technologies into Real-World Applications

At HICOOL 2026, Daxiang showcased its organoid-on-chip technologies and their applications while engaging with industry experts, researchers, entrepreneurs, and other participants across the innovation ecosystem.

These exchanges provided further insight into the evolving needs of pharmaceutical companies, research institutions, and other organizations seeking more human-relevant approaches to drug development, disease modeling, and safety assessment.

Daxiang Biotech develops integrated organoid and organoid-on-chip solutions spanning model development, microphysiological systems, instrumentation, and related research services. By combining organoid biology with microfluidic engineering, AI, and automation, the company is working to expand the use of human-relevant in vitro models across drug discovery and biomedical research.

The HICOOL recognition marks another milestone in Daxiang's continued development and reinforces the company's commitment to translating organoid-on-chip innovation into practical solutions for research and industry.